Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression
Clinical trial NCT03724968 · TERMINATED
Trial details
- NCT number
- NCT03724968
- Sponsor
- Elizabeth Davis
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-01-17
- Primary completion
- 2020-05-28
- Enrollment
- 2
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.